ArticleJournal of nanobiotechnology2019
Functionalized MoS
Article in Journal of nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 32 citations in OpenAlex.
- Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer.International journal of nanomedicine · 2026Review
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- First-principles calculations on monolayer WXNanoscale advances · 2024Article
- Hyperthermia Treatment as a Promising Anti-Cancer Strategy: Therapeutic Targets, Perspective Mechanisms and Synergistic Combinations in Experimental Approaches.Antioxidants (Basel, Switzerland) · 2022Review
- MoSBioactive materials · 2021Review
- Immunostimulatory Potential of MoSInternational journal of nanomedicine · 2020Article
- External and Internal Stimuli-Responsive Metallic Nanotherapeutics for Enhanced Anticancer Therapy.Frontiers in molecular biosciences · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMolybdenum disulfide (MoS
resultsThe nanocomposites (MoS
conclusionThe functionalized MoS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.